Izra-D 20 Capsule SR is a combination medication containing Domperidone 30 mg and Esomeprazole 20 mg, formulated to manage gastrointestinal disorders associated with acid reflux and delayed gastric emptying. Domperidone, a peripheral dopamine D2 receptor antagonist, enhances gastrointestinal motility by increasing the movement of the stomach and intestines, thereby facilitating gastric emptying and reducing symptoms such as nausea and vomiting. Esomeprazole, a proton pump inhibitor, suppresses gastric acid secretion by irreversibly inhibiting the H+/K+ ATPase enzyme system in the gastric parietal cells, providing effective relief from acid-related conditions such as gastroesophageal reflux disease (GERD), erosive esophagitis, and peptic ulcers. The sustained-release formulation of Izra-D 20 ensures prolonged therapeutic action, improving patient compliance by reducing dosing frequency. This combination is particularly beneficial in patients experiencing symptomatic acid reflux accompanied by delayed gastric emptying or dysmotility. Izra-D 20 should be used under medical supervision, with caution advised in patients with known hypersensitivity to either component, hepatic impairment, or cardiac conditions. Common adverse effects may include headache, dry mouth, and gastrointestinal disturbances. Regular monitoring and adherence to prescribed dosage are essential to optimize therapeutic outcomes and minimize potential side effects.